Linker Information
General Information of This Linker
| Linker ID |
LIN0QAKBX
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
A non-cleavable linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BIO-106 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced/metastatic solid tumors with disease progression post-standard therapy, measurable disease (RECIST 1.1 or bone-only), and ECOG 0-1. Exclusions cover drug hypersensitivity, cardiac dysfunction, active infections (HIV/HBV/HCV/SARS-CoV-2), and untreated CNS metastases.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)
|
||||
| Primary Endpoint |
The Phase 1 escalation period assesses safety (AEs, SAEs, DLTs) over 1 year to determine MTD, while the Phase 2 expansion period evaluates anti-tumor activity through ORR, DCR, DOR, PFS, and OS over 2 years.
|
||||
| Other Endpoint |
Phase 1 measures anti-tumor activity (ORR, DCR, DOR, PFS, OS) over 1 year, while Phase 2 monitors AESIs and AEs/SAEs over 2 years. PK parameters (Cmax, AUC) and anti-drug antibodies for BIO-106 are tracked across both phases.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
A phase 1/2 study of BIO-106 as monotherapy or in combination with pembrolizumab in patients with advanced cancers (starbridge-1).
|
||||
NJH395 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients must have HER2+ non-breast solid tumors refractory to standard therapies (ECOG ≤2) with biopsy-accessible lesions. Key exclusions include prior TLR7/8 treatment, cardiac dysfunction, autoimmune/active lung diseases, HIV, checkpoint inhibitor toxicity history, or QT-prolonging drug use. Additional protocol criteria may apply.
|
||||
| Administration Dosage |
As of July 01, 2020, 18 patients (10 males, 8 females; median age, 52.5 years [range, 42-74 years]) were enrolled in 5 dose cohorts (0.1-1.6 mg/kg).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03696771 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies
|
||||
| Primary Endpoint |
Dose-limiting toxicities (DLTs) incidence and severity will be assessed over 21 days, extending to 42 days in the second study phase. Adverse event data collection spans 2.5 years.
|
||||
| Other Endpoint |
PK profiles for NJH395 and metabolites will be tracked for 126 days, including Cmax/AUC measurements. Anti-drug antibody assessment and efficacy endpoints (ORR, CBR, PFS, DOR per RECIST v1.1/iRECIST) will be evaluated over 2.5 years. Tumor infiltrating lymphocyte changes will be monitored via IHC at specified treatment cycles (21-day intervals).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0%
|
|||
| Patients Enrolled |
Patients with nonbreast HER2+ advanced malignancies.
|
||||
| Administration Dosage |
5 dose cohorts (0.10-1.60 mg/kg).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03696771 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, multicenter, open-label dose finding study of NJH395, administered intravenously in patients with non-breast HER2+ advanced malignancies.
|
||||
References